Over the past decade, the use of selective serotonin reuptake inhibitors for the management of depression has increased dramatically, and preliminary evidence suggests that long-term use, for more than 1 or 2 years, accounts for much of this rise.\(^1\)–\(^3\) Clinical practice guidelines generally recommend a 6- to 9-month course following initial recovery after a first episode of depression and longer, sometimes indefinite, therapy after subsequent episodes, to prevent relapse.\(^4\)–\(^10\)

Long-term randomized controlled trials of antidepressants have typically used 1 of 2 possible designs, each answering different questions (Figure 1).\(^11\) The most widely used design is called the “discontinuation trial,” a 2-phase study in which all participants are initially treated with an open (unblinded) course of drug therapy. Participants attaining a certain response during the open-treatment phase enter the second phase, during which they are randomly assigned to continue active drug treatment or to receive placebo.\(^12\)–\(^14\) Discontinuation trials are believed to minimize the number of participants with depression who must be exposed to placebo. This advantage comes at a cost, since the results apply only to patients with a response to the medication, not to those who experience spontaneous recovery; furthermore, withdrawal symptoms may lead to an overestimate of the true effect of the medication. When this design is used to test long-term therapy with selective serotonin reuptake inhibitors for the treatment of depression, the results are difficult to interpret with confidence because rates of spontaneous recovery in depression are potentially high and because withdrawal effects can mimic depression.\(^13\)–\(^15\)

The second type of randomized trial used to test long-term therapy with selective serotonin reuptake inhibitors is a 2-arm parallel randomized controlled trial, hereafter referred to as a classic randomized controlled trial (Figure 1).\(^16\) In this type of trial, participants with acute depression...
Research

Sants are short-term studies. Fergusson and colleagues, continued earlier. To 36 months, relative to patients whose therapy was discontinued designs showed that, in a subgroup of patients who had a diagnosis of major depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders, third edition, third edition revised, or fourth edition) and who were randomly assigned to receive monotherapy with a selective serotonin reuptake inhibitor or placebo according to the classic 2-arm parallel randomized controlled trial design. Trials reporting a 1- to 2-week placebo run-in period were eligible, because such trials have been shown to yield unbiased estimates of effectiveness. We included participants 18 years of age or older. There were no comorbidity restrictions. Our definition of long-term treatment was treatment over a period of at least 6 months. Trials were limited to those published in English.

Two of us (D.D. and E.M.) checked the reference lists of all included studies for additional studies and secondary reports. Working independently, the same 2 coauthors checked search results to identify all suitable studies. Disagreement about trials to be included was resolved by consensus among 3 of the coauthors (J.G., D.M. and D.F).

We sought to examine the efficacy and acceptability of long-term therapy with selective serotonin reuptake inhibitors relative to placebo in the treatment of moderate to severe depression, including subgroups of patients with major chronic health conditions. We also examined a number of key indicators of the quality of evidence and its clinical importance.

**Methods**

**Literature search**

We searched for trials of fluoxetine, citalopram, escitalopram, fluvoxamine, paroxetine and sertraline. We updated the search strategy used in the previous systematic review of selective serotonin reuptake inhibitors and suicide to capture material indexed since the previous search date in MEDLINE (Ovid MEDLINE, to first week of May 2007) or EMBASE (Ovid EMBASE, to week 18 of 2007). The EMBASE search was limited to journals not indexed in MEDLINE. We searched the Cochrane Central Register of Controlled Trials for any studies published from 2003 to the second quarter of 2007. The search strategy combined the index terms associated with “serotonin uptake inhibitors” and the text terms “SSRI,” “fluoxetine,” “Prozac,” “sertraline,” “Zoloft,” “paroxetine,” “Paxil,” “fluvoxamine,” “Luvox,” “citalopram” and “Celexa”; we used the revised highly sensitive search strategy for controlled trials for the MEDLINE search and the Hedges balanced strategy for therapy for the EMBASE search. The updated search strategy is presented in Appendix 1 (available online at www.cmaj.ca/cgi/content/full/178/10/1293/DC2).

**Study selection**

To be eligible for this systematic review, trials had to involve patients who had a diagnosis of major depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders, third edition, third edition revised, or fourth edition) and who were randomly assigned to receive monotherapy with a selective serotonin reuptake inhibitor or placebo according to the classic 2-arm parallel randomized controlled trial design. Trials reporting a 1- to 2-week placebo run-in period were eligible, because such trials have been shown to yield unbiased estimates of effectiveness. We included participants 18 years of age or older. There were no comorbidity restrictions. Our definition of long-term treatment was treatment over a period of at least 6 months. Trials were limited to those published in English.

We included paroxetine and sertraline. We updated the search strategy used in the previous systematic review of selective serotonin reuptake inhibitors and suicide, identified 702 classic trials involving a total of 18,413 participants, the majority of which (93%) lasted less than 6 months.

A recent systematic review based mainly on studies with discontinuation designs showed that, in a subgroup of patients who experienced recovery while taking medications, long-term therapy with selective serotonin reuptake inhibitors reduced the chances of relapse by up to 70% for up to 36 months, relative to patients whose therapy was discontinued earlier. However, there has been no systematic review of classic randomized trials of long-term therapy with this drug class to determine the potential benefits in all patients with depression, including those with spontaneous recovery.

We sought to examine the efficacy and acceptability of long-term therapy with selective serotonin reuptake inhibitors relative to placebo in the treatment of moderate to severe depression, including subgroups of patients with major chronic health conditions. We also examined a number of key indicators of the quality of evidence and its clinical importance.

The following data were abstracted: characteristics of study participants, assignment to intervention, attrition, measurement of efficacy and acceptability.

**Data abstraction**

Standardized case-report forms were developed, pilot-tested and completed by 2 independent reviewers (D.D. and E.M.). The following data were abstracted: characteristics of study participants, assignment to intervention, attrition, measurement of efficacy and acceptability.

**Figure 1:** Two designs of randomized controlled trials used to investigate long-term antidepressant therapy.
population, interventions, study design, detailed inclusion and exclusion criteria, outcomes (including response and remission criteria), number of participants who completed the study and number of dropouts for any reason, method(s) of data analysis and trial funding. To handle missing data for primary outcomes, we used the published last-observation-carried-forward approach.

**Assessment of risk of bias**

We used the latest version of the Cochrane risk-of-bias tool to assess the risk of bias in the included studies (see Appendix 2, available online at www.cmaj.ca/cgi/content/full/178/10/1293/DC2). This instrument consists of 6 items. Two of the items assess the strength of the randomization process in preventing selection bias in the assignment of participants to interventions: adequacy of sequence generation and allocation concealment. The third item (blinding) assesses the influence of performance bias on the study results. The fourth item assesses the likelihood of incomplete outcome data, which raise the possibility of bias in effect estimates. The fifth item assesses selective reporting, the tendency to preferentially report statistically significant outcomes. It requires a comparison of published data with trial protocols, when such are available. The final item refers to other sources of bias that are relevant in certain circumstances, for example, in relation to trial design or setting. Examples include methodologic issues such as those related to crossover designs and early trial termination.

**Outcomes**

A priori, we identified 3 primary outcomes: response by study outcome, as defined by a 50% improvement in depression score relative to baseline; remission, as defined by a conventional remission cut-point (a score of 7 or less on the Hamilton rating scale for depression); and total number of dropouts as a proxy measure of overall treatment acceptability. We were also interested in key secondary outcomes, such as quality of life; the need for rescue therapy, such as admission to hospital, psychotherapy, pharmacotherapy or electroconvulsive therapy; self-harm (including attempted and completed suicide); and back-to-work status.

**Data analysis**

For each study, we calculated the odds ratio (OR) for each of the primary outcomes (response, remission and dropouts) with either selective serotonin reuptake inhibitor or placebo. Where clinically appropriate, we combined data from studies to estimate the pooled OR and 95% confidence intervals (CIs) using a DerSimonian and Laird random-effects model. Subgroup analyses were planned according to the presence or absence of comorbidities. An OR value greater than 1 indicates that more events occurred among patients who received selective serotonin reuptake inhibitors than among those who received placebo, and vice versa for OR values less than 1. Statistical consistency across randomized controlled trials was assessed by means of the $I^2$ statistic. Potential publication bias was determined by visual inspection of an inverted funnel plot.

**Results**

**Literature search**

We identified 2693 records, of which 2669 were eliminated after initial screening because of study duration, language of publication and relevance. The remaining 24 citations were added to 21 potentially eligible studies identified from the original systematic review for more detailed examination. Of the 45 eligible trials, we excluded 39. Thirty-two of these exclusions were based on study design (31 randomized discontinuation trials and 1 crossover trial). Six trials were excluded because they did not involve patients with diagnosed depression: 4 trials were for the prevention of poststroke depression, and 2 trials were for the prevention of depression in people who had experienced a response to antidepressant therapy. We excluded a 12-month classic randomized controlled trial because it involved only children and adolescents. (The excluded trials are listed in Appendix 3, available online at www.cmaj.ca/cgi/content/full/178/10/1293/DC2).

In the analyses reported here, we included 6 trials of 6–8 months’ duration in which a total of 1299 patients with moderate to severe depression were randomly assigned to receive antidepressant therapy or placebo (Figure 2, Table 1).
Table 1: Summary of classic randomized controlled trials included in the systematic review of selective serotonin reuptake inhibitors for unipolar depression (part 1 of 2)

| Study | Population* | Comparators | Completion data | Outcome measures | Duration, mo | Funding | Analysis |
|-------|-------------|-------------|-----------------|------------------|--------------|---------|----------|
| Detke et al\(^25\) | Major depressive disorder; single episode or recurrent; Clinical Global Impression-Severity score ≥ 4, Hamilton Depression Inventory 17 score ≥ 15 (multisite European study, source population unclear) | Paroxetine (20 mg) daily or placebo | • Total randomized = 179  
• Completion rate: paroxetine 78%, placebo 60%, overall 73%  
• Dropouts due to side effects: paroxetine 6%, placebo 7%  
• Dropouts due to lack of efficacy: paroxetine 6%, placebo 6% | • Response: 50% reduction in Hamilton Depression Inventory 17 score relative to baseline  
• Remission: Hamilton Depression Inventory score ≤ 7 | 8 | Eli Lilly & Co. | Last observation carried forward |
| Glassman et al\(^26\) | Depression after myocardial infarction; single episode or recurrent; Hamilton Depression Inventory score ≥ 18 (recruitment from multisite North American hospital) | Sertraline (50–200 mg) daily or placebo | • Total randomized = 369  
• Completion rate: sertraline 72%, placebo 73%, overall 73%  
• Dropouts due to side effects: sertraline 9%, placebo 6%  
• Dropouts due to lack of efficacy: sertraline 3%, placebo 3% | • Response: Clinical Global Impression-Improvement = 1 or 2 | 6.5 | Pfizer Inc. | Last observation carried forward |
| Gual et al\(^27\) | Alcohol dependence and major depression;† single episode or recurrent, with or without dysthymia (recruitment from single-site addictions treatment unit) | Sertraline (50–150 mg) daily or placebo | • Total randomized = 83  
• Completion rate: sertraline 55%, placebo 56%, overall 55%  
• Dropouts due to side effects: unknown  
• Dropouts due to lack of efficacy: unknown | • Response: ≥ 50% reduction in Montgomery Asberg Depression Rating Scale score relative to baseline  
• Remission: Hamilton Depression Inventory score < 7 | 6 | Unknown | Intention to treat (not carrying the last observation forward) |
| Hypericum Depression Trial Study Group\(^28\) | Major depression; single episode or recurrent; Hamilton Depression Inventory 17 score ≥ 20, Global Assessment of Functioning score ≤ 60 (outpatients from 12 academic and community clinics) | Sertraline (100 mg) daily or placebo | • Total randomized = 127  
• Completion rate: sertraline 24%, placebo 24%, overall 23%  
• Dropouts due to side effects (at 8 wk): sertraline 4%, placebo 3%  
• Dropouts due to lack of efficacy (at 8 wk): sertraline 6%, placebo 9% | • Full response: Clinical Global Impression-Improvement = 1 or 2 and Hamilton Depression Inventory 17 score < 8  
• Partial response: Clinical Global Impression-Improvement = 1 or 2 combined with Hamilton Depression Inventory 17 score between 9 and 12 and < 50% relative to baseline  
• Relapse: Clinical Global Impression-Severity = 4 and Hamilton Depression Inventory 17 score > 20 | 6 | National Center for Complementary Medicine, National Institute of Mental Health; Lichtwer Pharma; Pfizer | Last observation carried forward |
| Murray et al\(^29\) | Depression after stroke;‡ Montgomery Asberg Depression Rating Scale score ≥ 10 (recruitment from 4 stroke centres in Sweden) | Sertraline (50–100 mg) daily or placebo | • Total randomized = 123  
• Completion rate: sertraline 61%, placebo 51%, overall 56%  
• Dropouts due to side effects: sertraline 13%, placebo 8%  
• Dropouts due to lack of efficacy: sertraline 26%, placebo 36% | • Response: ≥ 50% reduction in Montgomery Asberg Depression Rating Scale score relative to baseline  
• Remission: Montgomery Asberg Depression Rating Scale score < 10 | 6 | Pfizer, AFA Insurances, Wallenberg Foundation | Both types of analysis done (last observation carried forward, and intention to treat) |
None of the eligible trials lasted longer than 12 months, and 5 of the 6 studies were commercially sponsored.

Study populations
Participants ranged in age from 18 to 89 years and had been recruited from psychiatric outpatient clinics, private research clinics and general medical wards or through public advertisements. In addition to participants with depression who were free of medical or psychiatric comorbidities, a range of clinical subgroups was represented, including participants with significant medical comorbidities (myocardial infarction, stroke) and alcohol dependence. Detailed inclusion and exclusion criteria of the 6 trials are summarized in Appendix 4 (available online at www.cmaj.ca/cgi/content/full/178/10/1293/DC2). In the 3 studies in which history of depression was reported,25,26,30 20%–50% of participants had a history of recurrent depression.

Interventions
Participants were randomly assigned to receive placebo or a selective serotonin reuptake inhibitor, specifically sertraline 50–200 mg/d,26–30 citalopram 20–60 mg/d30 or paroxetine 20 mg/d.25

Assessment of risk of bias
Overall, the mean dropout rate across all 6 trials was 48% (range 27%–77%). For most of the included studies, we were unable to ascertain the risk of bias for several items because of poor reporting. Four of the included studies had unclear sequence generation, 3 had unclear allocation concealment, 2 had unclear blinding, and all had unclear selective outcome reporting. Four had a high risk of bias for incomplete outcome data, and 4 were assessed as unclear for “other biases” (Table 2). Visual inspection of the funnel plots did not suggest asymmetry (e.g., publication bias).

Primary outcomes
For response to treatment (50% improvement in depression score relative to baseline), a pooled analysis of the 6 trials showed that selective serotonin reuptake inhibitors were superior to placebo at 6–8 months (OR 1.66, 95% CI 1.12–2.48; I² = 63.9%) (Figure 3). Subgroup analysis showed a statistically significant treatment effect among patients with depression who had no comorbidities (OR 2.13, 95% CI 1.11–4.08; I² = 76.8%) but not among those who had comorbidities (OR 1.32, 95% CI 0.84–2.06; I² = 30.8%) (Figure 3).

We obtained data on remission (score of 7 or below on the Hamilton rating scale for depression) from 4 trials.25,27,29,30 Overall, the pooled difference between selective serotonin reuptake inhibitors and placebo was not statistically significant (OR 1.46, 95% CI 0.92–2.32; I² = 38%). However, participants without comorbidities had a significantly higher remission rate if they were taking selective serotonin reuptake inhibitors than if they were taking placebo (OR 2.06, 95% CI 1.41–3.01; I² = 0%), whereas the difference for participants with comorbidities was not statistically significant (OR 0.87, 95% CI 0.44–1.72; I² = 6%) (Figure 4).

For our measure of overall acceptability (total dropouts)
there was no statistically significant difference between selective serotonin reuptake inhibitors and placebo (OR 0.87, 95% CI 0.67–1.14; I² = 21.3%) (Figure 5).

Secondary outcomes
Five of the 6 trials reported quality of life at the end of the trial (Table 3). Because a range of measures was used, we did not pool the data. One of the 5 trials reported improvements in all domains of a multidomain quality-of-life score, and another reported a quality-of-life summary statistic favouring selective serotonin reuptake inhibitors (p < 0.01), but the subscale breakdown was not reported. A third trial reported results of a 10-cm visual analogue scale that favoured selective serotonin reuptake inhibitors, and a fourth reported quality-of-life improvements restricted to mood subscales, with no statistically significant differences in other subscales. None of the trials provided information on the need for specific rescue therapies, including admission to hospital for psychiatric reasons, psychotherapy, pharmacotherapy or electroconvulsive therapy. Four trials did not specifically report on suicide or self-harm. In the 2 trials that reported on suicide or self-harm, there was a total of 1 completed suicide among patients receiving placebo and none among patients receiving selective serotonin reuptake inhibitor. Information on back-to-work status was not reported in any of the trials. One of the 6 trials stratified outcomes by the number of previous

| Study                                      | Sequence generation | Allocation concealment | Blinding | Incomplete outcome data | Selective outcome reporting | Other biases |
|--------------------------------------------|---------------------|------------------------|----------|-------------------------|----------------------------|--------------|
| Detke et al25                              | Unclear             | Unclear                | Low risk | High risk               | Unclear                    | Unclear      |
| Glassman et al26                           | Unclear             | Unclear                | Low risk | Unclear                 | Unclear                    | Unclear      |
| Gual et al27                               | Low risk            | Low risk               | Unclear  | High risk               | Unclear                    | Low risk     |
| Hypericum Depression Trial Study Group28    | Low risk            | Low risk               | Low risk | Unclear                 | Unclear                    | Unclear      |
| Murray et al29                             | Unclear             | Low risk               | Unclear  | High risk               | Unclear                    | Low risk     |
| Stahl30                                     | Unclear             | Unclear                | Unclear  | High risk               | Unclear                    | Unclear      |

* Ratings based on Cochrane risk-of-bias tool and explained in Appendix 2 (available online at www.cmaj.ca/cgi/content/full/178/10/1293/DC2).
depressive episodes and reported a higher response rate among patients with a history of recurrent depression.²⁶

**Interpretation**

No trials assessing the efficacy of selective serotonin reuptake inhibitor therapy over a period of more than 1 year met our eligibility criteria. Only 6 trials met our eligibility criteria; these studies, which had a moderate risk of bias, had randomly assigned a total of 1299 participants with depression to receive placebo or selective serotonin reuptake inhibitor and had followed both groups for 6–8 months. The mean dropout rate after 6–8 months was 48% (range 27%–87%), which exceeds the 15% maximum previously recommended for studies lasting longer than 3 months.³¹ High dropout rates tend to reduce the level of confidence in the internal validity of trial results, as well as their applicability to general clinical practice. The only classic randomized clinical trial extending past 8 months that we identified was excluded from our review (see Appendix 3, at www.cmaj.ca/cgi/content/full/178/10/1293/DC2). That study involved children and adolescents with depression, and participants with a response to medication or placebo were followed for 12 months. However, with an overall completion rate of only 16%, the trial was difficult to evaluate.

We observed statistically significant improvements in response to treatment but not in remission or acceptability (which might have been due to lack of power) after 6–8 months of selective serotonin reuptake inhibitor therapy. The effects appeared greater in patients without comorbidities. However, given the limited reporting of participants’ course of illness, we were unable to determine whether particular subgroups, such as those with highly recurrent depression, benefited more than those with single episodes. Furthermore, we found few data about the long-term effects of selective serotonin reuptake inhibitors on a range of important clinical outcomes, such as time off work, the need for co-interventions and self-harm, relative to those of placebo.

The study populations had been recruited from a range of settings, including psychiatric clinics, general medical hospitals and private community clinics. Groups with a higher prevalence of severe or recurrent depression may benefit most from antidepressants, and the distribution of more severe depressive illness may differ across these settings.³²–³⁴

One of the strengths of our systematic review is that it focused on classic long-term randomized controlled trials of selective serotonin reuptake inhibitors for the treatment of depression. Previous reviews included and were dominated by studies with discontinuation designs, which are difficult to interpret and which may overestimate the benefits of treatments.

Our study has several limitations. Because of resource constraints, we included only studies published in English, but this restriction is unlikely to have biased our results.³⁵,³⁶ We did not detect any evidence of publication bias.

The main limitations of our review reflect the weaknesses of the included studies. The studies were at moderate risk of bias and failed to report key methodologic issues. No study reported data beyond 12 months. The most commonly reported outcome was “response to treatment” rather than “full remission.” Response was defined in terms of a 50% improvement in depression scores relative to baseline, whereas “full remission” was defined by pre-established cut-points on depression scores. Full remission from depression correlates with better longer-term functional recovery, lower risk of relapse and
higher levels of patient satisfaction than partial response without remission. Another limitation is that 4 of the 6 included trials reported outcomes in terms of the “last observation carried forward,” a method that may underestimate true treatment effects in short-term trials but overestimate active interventions in long-term trials. Five of the 6 studies were commercially sponsored. This might have led to an exaggeration of treatment effects, since industry-sponsored trials have been shown to be 4 times as likely as independent studies to demonstrate positive effects of the sponsor’s drug.

Similar to concerns with shorter-term trials of selective serotonin reuptake inhibitors, the study participants in the included trials may not be representative of those seen in everyday practice. For example, 5 of the 6 trials excluded patients with substance abuse, a common comorbidity, and all trials excluded patients with suicidal ideation, one of the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition.

Conclusion

Despite the widespread use of long-term therapy with selective serotonin reuptake inhibitors, relatively few trials have compared long-term outcomes between patients with depres-

| Study                      | Drug, n/N | Placebo, n/N | OR (95%CI) |
|----------------------------|-----------|--------------|------------|
| **Depression with comorbidity** |           |              |            |
| Gual et al<sup>27</sup>     | 20/44     | 17/39        | 1.08 (0.45-2.57) |
| Murray et al<sup>29</sup>   | 24/62     | 30/61        | 0.65 (0.32-1.34) |
| Glassman et al<sup>26</sup>| 53/188    | 49/183       | 1.07 (0.68-1.69) |
| Subtotal                    | 97/294    | 96/283       | 0.95 (0.67-1.35) |
| **Depression without comorbidity** |        |               |            |
| Detke et al<sup>25</sup>    | 19/86     | 37/93        | 0.43 (0.22-0.83) |
| Hypericum Depression Trial Study Group<sup>28</sup> | 83/111 | 89/116 | 0.90 (0.49-1.65) |
| Stahl<sup>30</sup>          | 140/209   | 73/107       | 0.95 (0.57-1.56) |
| Subtotal                    | 242/406   | 199/316      | 0.72 (0.44-1.17) |
| Overall                     | 339/700   | 295/599      | 0.87 (0.67-1.14) |

Table 3: Secondary outcomes in classic randomized trials of selective serotonin reuptake inhibitors included in the systematic review

| Study                          | Rescue therapy* | Back-to-work status | Suicide, suicide attempt or self-harm | Overall quality-of-life |
|--------------------------------|-----------------|---------------------|---------------------------------------|-------------------------|
| Detke et al<sup>25</sup>       | Not reported    | Not reported        | 1 suicide (placebo group)              | Sheehan Disability Scale (favoured drug) |
| Glassman et al<sup>26</sup>    | Not reported    | Not reported        | Not reported                           | Not reported            |
| Gual et al<sup>27</sup>        | Not reported    | Not reported        | Not reported                           | Medical Outcomes Study 36-Item Short Form (favoured drug) |
| Hypericum Depression Trial Study Group<sup>28</sup> | Not reported | Not reported | “No serious adverse events” | Not reported at end point |
| Murray et al<sup>29</sup>      | Not reported    | Not applicable†     | Not reported                           | Visual analogue scale (favoured drug) |
| Stahl<sup>30</sup>             | Not reported    | Not reported        | Not reported                           | Symptom Checklist-56 (favoured drug) |

*Medications, psychotherapy, electroconvulsive therapy or admission to hospital.
†Mean age of participants (who had depression following stroke) was 70 years.
sion who recover spontaneously and those who recover because of medication. Most treatment guidelines recommend a minimum of 6–9 months of antidepressant treatment following initial recovery from depression. Our observations, based on limited evidence, support current recommendations that treatment continue for at least 6–9 months after recovery from an episode of depression, particularly in those without major comorbidities. Longer-term treatment should be undertaken only in selected cases and with an appreciation of the uncertainties surrounding the practice. Future studies should examine long-term use of selective serotonin reuptake inhibitors in depression using clinically relevant outcomes for all patients with depression, including those who experience spontaneous resolution.

This article has been peer reviewed.

Competing interests: None declared.

Disclaimer: Dorian Deshauer is a coauthor of this article. As an associate editor of CMAJ, he was not involved in the selection of peer reviewers or the vetting of the manuscript before its acceptance.

Contributors: Dorian Deshauer, David Moher, Dean Fergusson and Jeremy Grimshaw contributed to designing the systematic review, performing the statistical analyses, interpreting the results and writing the manuscript. Dorian Deshauer, Dean Fergusson and Ester Moher contributed to the identification of studies. Dorian Deshauer and Ester Moher contributed to data abstraction. Margaret Sampson designed and implemented the search strategy. All of the authors critically revised the manuscript and approved the final version.

Acknowledgement: David Moher is funded by a University of Ottawa Research Chair.

REFERENCES

1. Raymond CB, Morgan SG, Caetano PA. Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence. Psychiatr Serv 2007;58:79-84.
2. Petty DR, House A, Knapp P, et al. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing 2006;35:23-6.
3. Meijer WE, Heerdink ER, Leefker WS, et al. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2006;60:57-60.
4. Depression: management of depression in primary and secondary care. London (UK): National Institute for Health and Clinical Excellence; 2004.
5. Major depression in adults in primary care. Bloomington (MN): Institute for Clinical Systems Improvement; 2004.
6. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:63-6.
7. Adult primary care depression guidelines. Oakland (CA): Care Management Institute, Kaiser Permanente; 2004.
8. Canadian Psychiatric Association; Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46(Suppl 1):1S-92S.
9. Zimmerman M, Posternak M, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 2005;20:445-60.
10. Treatment of major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2006;178:296-305.
11. Detke MJ, Wiltsie CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:579-70.
12. Glassman AH, O’Connor CM, Calif RJ, et al. Sertraline treatment of major depression in patients with acute M or unstable anemia. JAMA 2002;288:701-9.
13. Gual A, Ballecs M, Torres M, et al. Sertraline for the prevention of relapse in depressed alcohol-dependent patients with a mood disorder depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003;38:169-215.
14. European Depression Trial Investigators. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;288:107-14.
15. Murray V, von Arbin M, Barfi A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression or less severe major depression. J Clin Psychiatry 2005;66:708-16.
16. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:804-901.
17. Treatment of major depression. Vol. 2. Rockville (MD): US Department of Health and Human Services; Agency for Healthcare Policy and Research; 1993.
18. Chatterton J, Kendrick T; THREAT Study Group. Protocol for the THREAT study for antidepressants in primary care: methods and rationale. J Clin Epidemiol 2004;57:767-96.
19. Glanville JM, Lefebvre C, Miles JN, et al. How to identify randomized controlled interventions. Version 3.0.0 (Oxford, UK): The Cochrane Collaboration; 2008 Feb. Table: www.cochrane-handbook.org (accessed 2008 May 23).
20. Montori VM, Devereaux PJ, Adhikari NKJ, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-7.
21. Barbut C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2006;178:793-9.
22. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.0 (Oxford, UK): The Cochrane Collaboration; 2008 Feb. Table: www.cochrane-handbook.org (accessed 2008 May 23).
23. Zimmerman M, Posternak M, Armour T, et al. Managing database overlap in systematic reviews using Random Citation Matcher: case studies using Scopus. J Med Libr Assoc 2006;94:130-9.
24. Gual A, Ballecs M, Torres M, et al. Sertraline for the prevention of relapse in depressed alcohol-dependent patients with a mood disorder depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003;38:169-215.
25. Detke MJ, Wiltsie CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:579-70.
26. Glassman AH, O’Connor CM, Calif RJ, et al. Sertraline treatment of major depression in patients with acute M or unstable anemia. JAMA 2002;288:701-9.
27. Gual A, Ballecs M, Torres M, et al. Sertraline for the prevention of relapse in depressed alcohol-dependent patients with a mood disorder depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003;38:169-215.
28. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:307-14.
29. Murray V, von Arbin M, Barfi A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression or less severe major depression. J Clin Psychiatry 2005;66:708-16.
30. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:804-901.
31. Treatment of major depression. Vol. 2. Rockville (MD): US Department of Health and Human Services; Agency for Healthcare Policy and Research; 1993.
32. Chatterton J, Kendrick T; THREAT Study Group. Protocol for the THREAT study for antidepressants in primary care: methods and rationale. J Clin Epidemiol 2004;57:767-96.
33. Zimmerman M, Glassman AH, Harrison DJ. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005;66:346-52.
34. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5(2):e45.
35. Pham B, Lawson M, Klassen T, et al. Language of publication restrictions gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol 2007;60:706-7.
36. Moher D, Pham B, Klassen TP, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 2005;58:964-72.
37. Zimmerman M, Posternak M, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 2004;19:215-20.
38. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of anti-depressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30:445-60.
39. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:555-62.
40. McInnes I, Pham B, Tugwell P, et al. Does the inclusion of grey literature influence the estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228-31.
41. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research output and quality: a systematic review. BMJ 2003;326:167-70.
42. Zimmerman M, Mattia J, Posternak M. Are subjects in pharmaceutical treatment trials of depression representative of patients in routine clinical practice? Ann Intern Med 2001;135:495-73.

Correspondence to: Dorian Deshauer, Institute of Mental Health Research, 1145 Carling Ave., Ottawa ON K1Z 7K4; fax 613 333-5758; deshauer1@sympatico.ca